Ventana Medical Systems, Inc.05/17/2013
Ventana Medical Systems Introduction
Through innovative solutions for H&E, immunohistochemistry (IHC) and in situ hybridization (ISH), special stains, advanced workflow and digital pathology, Ventana empowers anatomic pathologists and laboratory professionals to increase testing efficiency. Our intuitive, integrated slide staining and workflow management platforms optimize laboratory operations to minimize errors, support diagnosis, and inform treatment decisions for anatomic pathology professional
Ventana Medical Systems, Inc.08/15/2013
Ventana Case Study: Yuma Regional Medical Center and digital pathology
At Yuma Regional Medical Center in Yuma, Arizona, the anatomical pathology lab has adopted cutting edge digital pathology solutions from Ventana Medical Systems, Inc. to increase their efficiencies and to assist in better patient care.
Biotech Gore Tag Endoprosthesis
The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 30 million innovative Gore Medical Devices have been implanted worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery.
W.L. Gore and Associaties, Inc. the 2013 Arizona Bioscience Company of the Year
W.L. Gore & Associates was honored at the 2013 AZBio Awards as the Arizona Bioscience Company of the Year by the Arizona Bioindustry Association in recognition of the development of the extensive Gore Medical family of products including vascular grafts, endovascular and interventional devices, and surgical meshes by its world class team of innovators in Flagstaff and Phoenix. In this video you will learn about Gore and also gain insights on what we need to do together to continue our Arizona Bioscience Industry growth from Gore's Kurt Long.
SynCardia Systems, Inc.05/29/2013
Heart of a Champion - Justin Ryder
Former Semi-Pro Arena Football Player and Father of 3 Had Surgery for an Enlarged Heart at Age 18 Justin Ryder has battled heart problems nearly all his adult life. But after multiple surgeries, the 35-year-old Las Vegas, Nev., resident finally has a ticker that works - SynCardia's temporary Total Artificial Heart. Running out of options with his patched-up natural heart, Ryder had an artificial one implanted in early December at the University of Arizona Medical Center. It keeps him going, literally, while he awaits a donor heart.
Company Presentation: Invoy Technologies, LLC
Exhaled Breath: A Portal for Pain-Free Biochemical Analysis Invoy is engaged in the development and commercialization of breath analysis devices for a broad range of applications. Invoy plans to offer patients the ability to monitor their health in the convenience of their own home – with a prescription-based breath analysis device called the Voyager. The process is pain-free and the results are quick and accurate; giving patients peace of mind and confidence in using this new-to-the-market device.
2012 AZBio Fast Lane Award Winner - Ulthera
Beauty and Growth – Ulthera, Inc Ulthera’s mission is to work with physicians to provide therapeutic ultrasound to improve the appearance and health of patients worldwide. The company is not only defined by its proprietary technology, but also its people. Ulthera’s team consists of experts in their respective fields who are aligned by the strength of the company’s mission and its leadership. Ulthera was founded in 2004 to leverage seven years of prior scientific research in therapeutic ultrasound for aesthetic and medical applications. In 2009, the Ulthera® System received FDA approval in the United States and is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® – the procedure enabled by the System – is a non-invasive treatment of the face to achieve a brow lift. Ulthera’s robust scientific foundation and relentless pursuit of superior clinical outcomes have resulted in the rapid global uptake of the Ulthera platform. As Ulthera continues to develop and provide more applications for its platform, the company also remains committed to bringing value to physicians and their patients. In 2006, Matt Likens was hired as President and CEO of Ulthera by founder and owner Michael Slayton, Ph. D, with the expectation of obtaining FDA approval for Ulthera’s product and service (known as Ultherapy) within three months. Less than two years into his tenure at Ulthera, Matt found himself navigating this venture capital backed start-up though the worst economic downtown since the Great Depression. The Company also found itself facing an increasing skeptical and less commercially friendly US Food and Drug Administration (FDA) regime. With both of these risks significantly threatening the Company’s viability, Matt decided to change the Company’s regulatory pathway and focus by obtaining CE Mark from the European Union prior to obtaining FDA clearance. If this bet paid off, Ulthera’s regulatory runway would be significantly reduced and the Company would be able to generate sales in the European market. These revenues would also allow the Company to lessen the need to obtain additional venture capital financing thus reducing additional dilution to the Company’s current shareholders. While risky, the core of this decision was based on the multinational experience Likens attained at Baxter and his general entrepreneurial nature. The bet ultimately paid off. Today, Ulthera is a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. More than 1,000 Ulthera Systems have been sold globally while treatments performed using the System have surpassed 100,000.
Nasseo moves into the Fast Lane
Nasseo, Inc. is a start-up medical device company developing an implant surface modification technology to provide patients and clinicians with the next generation of dental and orthopedic implants. Over the past 18 months the company has achieved very impressive milestones and is in the Fast Lane to delivering a new platform technology that benefits patients in several compelling markets. In 2013 NASSEO was accepted into the BioInspire Medical Device accelerator in Peoria, AZ. In addition to mentoring and support, NASSEO received a $300,000 investment of seed funding from the highly competitive program. NASSEO was also named the 2013 Innovation Challenge Winner by the Arizona Commerce Authority (ACA) in its spring Arizona Innovation Challenge securing $250,000 for the commercialization of its first product, the TiArray™ Dental Implant which received FDA approval in 2013.